Risk Factors for Shoulder Joint Motion Restriction

May 25, 2022 updated by: Nilufer Kablan, Istanbul Medeniyet University

Risk Factors for Shoulder Joint Motion Restriction in Breast Cancer Survivors

In breast cancer patients, limitation of shoulder joint movement may occur following cancer treatment. Shoulder limitation causes a significant decrease in the patient's participation in activities of daily living. The aim of the study is to define these limitations, to evaluate in detail all the structures that cause the problem, and to determine the causes of the limitations in patients with shoulder joint movement limitation developed after breast cancer survivors.

Study Overview

Study Type

Observational

Enrollment (Anticipated)

72

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Istanbul, Turkey
        • Istanbul Medeniyet University
        • Contact:
        • Principal Investigator:
          • Nilüfer Kablan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Breast cancer survivors with or without shoulder joint restriction will be evaluated

Description

Inclusion Criteria:

  • Women between the ages of 30-60
  • Having breast cancer treatment within 5 years

Exclusion Criteria:

  • Not having agreed to participate in the study
  • Presence of additional orthopedic (scoliosis, etc.), neurological (multiple sclerosis, stroke, etc.) and rheumatological diseases (ankylosing spondylitis, rheumatoid arthritis, etc.) that will affect upper extremity functions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Experimental Group
Breast cancer survivors with shoulder joint motion restriction
Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain
muscle tones will be measured with myotonPro on centers of coordination located along along the myofascial chain
creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain
The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.
measurements will be taken by the thermographic camera
Pain will be evaluated by visual analog scale (VAS)
Pain pressure threshold will be evaluated by a digital algometer
The grip strength of both hand will be evaluated by "hand-held" dynamometer.
Control group
Breast cancer survivors without shoulder joint motion restriction
Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain
muscle tones will be measured with myotonPro on centers of coordination located along along the myofascial chain
creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain
The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.
measurements will be taken by the thermographic camera
Pain will be evaluated by visual analog scale (VAS)
Pain pressure threshold will be evaluated by a digital algometer
The grip strength of both hand will be evaluated by "hand-held" dynamometer.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
measurement of tissue stiffness (N/m)
Time Frame: Baseline
Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain
Baseline
measurement of passive muscle tone (Hz)
Time Frame: Baseline
muscle tones will be measured with myotonPro on centers of coordination located along the myofascial chain
Baseline
measurement of creep of tissue
Time Frame: Baseline
creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain
Baseline
measurement of the range of shoulder joint motion
Time Frame: Baseline
The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
measurement of skin temperature
Time Frame: Baseline
measurements will be taken from the area covering 3 cm of the surgical incision with a P45 thermographic camera with high thermal sensitivity
Baseline
measurement of pain
Time Frame: Baseline
Pain will be evaluated by visual analog scale (VAS). In the scale, the patient is asked to mark the most appropriate pain intensity on a scale ranging from 0 (no pain) to 10 (tolerable pain). The higher the score, the greater the pain intensity.
Baseline
measurement of pain pressure threshold
Time Frame: Baseline
Pain pressure threshold will be evaluated by a digital algometer
Baseline
measurement of grip strength
Time Frame: Baseline
The grip strength of both hand will be evaluated by "hand-held" dynamometer.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

August 15, 2022

Primary Completion (Anticipated)

August 15, 2023

Study Completion (Anticipated)

February 15, 2024

Study Registration Dates

First Submitted

May 18, 2022

First Submitted That Met QC Criteria

May 18, 2022

First Posted (Actual)

May 23, 2022

Study Record Updates

Last Update Posted (Actual)

May 31, 2022

Last Update Submitted That Met QC Criteria

May 25, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 2022/0226

Plan for Individual participant data (IPD)

Study Data/Documents

  1. Individual Participant Data Set
    Information identifier: 18192154
  2. Individual Participant Data Set
    Information identifier: 25977305
  3. Individual Participant Data Set
    Information identifier: 26079868
  4. Individual Participant Data Set
    Information identifier: 29332760
  5. Individual Participant Data Set
    Information identifier: 32031629
  6. Individual Participant Data Set
    Information identifier: 32767329
  7. Individual Participant Data Set

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer Survivors

Clinical Trials on measurement of tissue stiffness (N/m)

Subscribe